LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans.

John D Bagdade, Bernd Jilma, Lisa C Hudgins, Petar Alaupovic, Carrie E McCurdy

Journal: Lipids in health and disease 2018;17(1):127

PMID: 29807532

Abstract

BACKGROUND

Previous studies of lipoproteins in patients with sepsis have been performed on density fractions isolated by conventional ultracentrifugation that are heterogeneous and provide no information about the cargo of apoproteins present in the immunochemically distinct subclasses that populate the density classes. Since apoproteins are now known to have important roles in host defense, we have separated these subclasses according to their apoprotein content and characterized their changes during experimental endotoxemia in human volunteers.

METHODS

We have studied apoB- and apoA containing lipoprotein subclasses in twelve healthy male volunteers before and for 8 h after a single dose of endotoxin (ET; 2 μg/kg) to stimulate inflammation.

RESULTS

After endotoxin, TG, TC, apoB and the apoB-containing lipoprotein cholesterol-rich subclass LpB and two of the three triglyceride-rich subclasses (TGRLP: Lp:B:C, LpB:C:E+ LpB:E) all declined. In contrast, the third TGRLP, LpA-II:B:C:D:E ("complex particle"), after reaching a nadir at 4 h rose 49% above baseline, p = .006 at 8 h and became the dominant particle in the TGRLP pool. This increment exceeds the threshold of > 25% change required for designation as an acute phase protein. Simultaneous decreases in LpA-I:A-II and LpB:C:E + LpB:E suggest that these subclasses undergo post-translational modification and contribute to the formation of new LpA-II:B:C:D:E particles.

CONCLUSIONS

We have identified a new acute phase lipoprotein whose apoprotein constituents have metabolic and immunoregulatory properties applicable to host defense that make it well constituted to engage in the APR.

Address: Department of Human Physiology, University of Oregon, 122c Esslinger Hall, Eugene, OR, 97403, USA. [email protected].; Department of Medicine and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.; Department of Medicine, Weill Cornell Medical College and the Rogosin Institute, New York, NY, 10065, USA.; Lipid and Lipoprotein Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.; Department of Human Physiology, University of Oregon, 122c Esslinger Hall, Eugene, OR, 97403, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.